Personalized Oncology with Artificial Intelligence: The Case of Temozolomide

Nicolas Houy () and François Le Grand
Additional contact information
Nicolas Houy: EM - EMLyon Business School

Post-Print from HAL

Abstract: Purpose: Using artificial intelligence techniques, we compute optimal personalized protocols for temozolomide administration in a population of patients with variability. Methods: Our optimizations are based on a Pharmacokinetics/Pharmacodynamics (PK/PD) model with population variability for temozolomide, inspired by Faivre et al. [10] and Panetta et al. [25,26]. The patient pharmacokinetic parameters can only be partially observed at admission and are progressively learned by Bayesian inference during treatment. For every patient, we seek to minimize tumor size while avoiding severe toxicity, i.e. maintaining an acceptable toxicity level. The optimization algorithm we rely on borrows from the field of artificial intelligence. Results: Optimal personalized protocols (OPP) achieve a sizable decrease in tumor size at the population level but also patient-wise. The tumor size is on average 67.2 g lighter than with the standard maximum-tolerated dose protocol (MTD) after 336 days (12 MTD cycles). The corresponding 90% confidence interval for average tumor size reduction amounts to 58.6–82.7 g. When treated with OPP, less patients experience severe toxicity in comparison to MTD. Major findings: We quantify in-silico the benefits offered by personalized oncology in the case of temozolomide administration. To do so, we compute optimal personalized protocols for a population of heterogeneous patients using artificial intelligence techniques. At each treatment day, the protocol is updated by taking into account the feedback obtained from patient's reaction to the drug administration. Personalized protocols greatly differ from each other, and from the standard MTD protocol. Benefits of personalization are very sizable: tumor sizes are much smaller on average and also patient-wise, while severe toxicity is made less frequent.

Keywords: Optimization; Personalized oncology; Artificial intelligence; AI; Pharmacokinetics; Pharmacodynamics (search for similar items in EconPapers)
Date: 2019-08-01
References: Add references at CitEc
Citations:

Published in Artificial Intelligence In Medicine, 2019, 99

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-02312394

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().